Europe - MM&M - Medical Marketing and Media


Kadcyla pulled in $173 million in sales since its introduction in the US market in February

Britain’s NICE sidelines Kadcyla

Britain’s National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche’s breast cancer drug will remain off the National Health Services formulary because it is too expensive.